EPElizaveta A. Prosekina

Elizaveta A. Prosekina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizaveta A. Prosekina has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunomonitoring in GD2-positive Wilms tumor immunotherapy. A case report

    by S. A. Kulyova, E. A. Prosekina, I. A. Baldueva, K. M. Borokshinova, O. E. Savelieva, M. V. Rubanskaya, S. R. Varfolomeeva

    Over the past decades, survival rate for patients with refractory tumors have been increasing at a very slow. The success of the last decade has been the formation of new classes of drugs – targeting, created to affect certain intracellular molecular targets, as well as immuno-oncological, aimed at surface receptor targets. This article presents a clinical case of a patient with a GD2-positive Wilms tumor who received chemoimmunotherapy using anti-GD2 monoclonal antibodies as reinduction treatment. Within the framework of peripheral blood immunomonitoring, the picture of the main parameters of cellular immunity, as well as their dynamics during treatment, was assessed. During the analysis of the immune status dynamics, all observed parameters associated with an unfavorable outcome, namely the number of regulatory T cells and myeloid suppressor cells, were at low levels. The exception was the absolute neutrophils to lymphocytes ratio, which exceeded the norm by 3–4 times. In addition, after 2 courses of chemoimmunotherapy, the number of NK (CD3 – CD16 + CD56 + ) and activated HLA – DR + CD8 + cells, which are also present in the immunosuppressive lymphocyte cluster, increased. Subsequently, despite an increase in the levels of immunoactivating subpopulations of cells by 1.5–3.0 times (with the exception of γδ T cells), the immunosuppressive pattern of lymphocytes also reacted upward, but the increase in its indicators was not so significant. Again, the exception was regulatory T cells, the number of which tripled. These changes were associated with the progression of the malignant disease. A combination of immuno-oncology agents may need to be considered in the future to enhance T cell effector functions and/or inhibit immunosuppressive pathways. In this context, analyzed systemic immunomarkers in peripheral blood can be used to optimize the combination of chemoimmunotherapy.

  • Open Access

    Cardiovascular toxicity of antiGD2-specific monoclonal antibodies in a patient with osteosarcoma. A clinical case report

    by Alika A. Kulyova, Svetlana A. Kulyova, Rina I. Khabarova, Evgeniy M. Senchurov, Elena A. Mikhailova, Ksenia M. Borokshinova, Valeria S. Ignatova, Elizaveta A. Prosekina, Tatiana L. Vershinina

    Immunotherapy is one of the most effective methods of cancer therapy. There are five main groups of immunotherapy, including treatment with chimeric antigen receptor T cells, checkpoint inhibitors, anticancer vaccines, antibody-based targeted therapies, and oncolytic viruses. On the adult cohort of patients, immunotherapy has been proven to increase the survival rate of patients with cancer. At the same time, in some patients, it can cause an immune-mediated damage and contribute to unfavorable heart immune modulation and heart failure. Immunotherapy can target many components of the cardiovascular system, including the myocardium, blood vessels, electrical wiring, and the pericardium. Activated T lymphocytes (CD4 + and CD8 + T cells) penetrate the heart tissue and skeletal targets, which leads to local inflammation and damage. Additional theoretical mechanisms for side effects include autoantibody recognition of self-antigens and T cell-mediated damage to cardiomyocytes and stressed endothelial cells. After treatment with T cells, the level of proinflammatory cytokines may increase, which is often the cause of cytokine release syndrome, the occurrence of which is considered a “targeted, non-neoplastic” effect. Proinflammatory cytokines can have negative cytotoxic effects on cardiomyocytes, resulting in reduced myocardial contractility, cardiomyopathy, and hypotension. This review presents a clinical case of cardiotoxicity due to the use of antiGD2 monoclonal antibodies in a child with a refractory form of osteosarcoma.

  • DDAH1 protein: biological functions, role in carcinogenesis processes

    by E.A. Prosekina, V.A. Shapkina, A.E. Karpov, E.YU. Fedorutseva, A.S. Artemyeva

    Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) is an essential enzyme capable of degrading asymmetric dimethylarginine, which is an endogenous inhibitor of nitric oxide synthase. Increased expression of DDAH1 and subsequent increased NO production are associated with carcinogenesis. In particular, DDAH1 is involved in the creation of a vascular network by tumor cells, vasculogenic mimicry, which is closely associated with tumor progression and poor patient prognosis. This is the reason why DDAH1 may be a potential therapeutic target for the treatment of cancer.


  • Open Access

    Results of chemoimmunotherapy for refractory/recurrent GD2-positive bone and soft tissue sarcomas in children. Two centers first experience

    by S. A. Kulyova, S. R. Varfolomeeva, K. I. Kirgizov, E. A. Prosekina, O. M. Romantsova, G. A. Sakhautdinov, K. M. Borokshinova, Yu. K. Semenova, T. V. Gorbunova, R. I. Khabarova, et al.

    Background. In the literature, information on the overexpression of disialoganglioside GD2 on the cells of malignant neoplasms is not uncommon. In this regard, this marker should be considered as a tumor-associated antigen, which may be a target on the cell surface in patients with poor prognosis.The aim of the study – improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated (unSA) and bone sarcomas) by incorporating targeted immunotherapeutic options (immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.Materials and methods. Ten patients with GD2-positive relapsed/refractory soft tissue sarcomas (STS, n = 4), osteosarcomas (OS, n = 2), Ewingʼs sarcomas (ES, n = 4) and unSA (n = 1) were included in the study. The gender ratio was 2.3:1 (boys:girls). The mean age at the time of inclusion in the study was 12 ± 2 years. The most of all patients (80 %) had a status of “primary resistant disease”. GD2 quantitative expression level was 29 ± 11 % (0.9 to 85 %). Patients were represented by deeply pretreated patients who received 8 to 25 cycles of 2+ line chemotherapy (mean 13). A total of 7 patients completed the full reinduction treatment (6 cycles of chemoimmunotherapy). All patients received anti-GD2 MA 100 mg/m2 as an intravenous 5-day infusion every 4 weeks, and treatment was continued until disease progression or 6 cycles. Fifty-two cycles of immunotherapy were performed.Results. Pain syndrome was the most frequently diagnosed (after 16 cycles, or in 30.7 % of cases); 5 (9.6 %) cycles each were accompanied by diarrhea, cytokine release syndrome, and increased capillary permeability syndrome. The immediate results varied according to the histological subtype of the tumor. The overall objective response rate was 43 % (3/7): 2 patients achieved complete remission (CR) and one achieved partial remission (PR). The disease control rate (CR + PR + stable) was 86 % (6/7). The clinical response rate 6 months after completion of chemoimmunotherapy ranged from 0 % (2/2) in ES to 50 % (1/2) in OS. In 43 % (3/7) of evaluable patients, disease progression was diagnosed after a mean of 5 months. At follow-up after 12 and 24 months, CR persisted in all patients with STS (100 %). Progression-free survival (PFS) in patients with STS at 6, 12 and 24 months was 100 % (PFS6, PFS12, PFS24, respectively). PFS6 in OS and ES patients was 100 % and 50 %, respectively, gradually decreasing to 0 %. The study revealed a very strong positive straight-line positive functional correlation between quantitative GD2 expression and progression-free survival (r = 0.971, p = 0.00006).Conclusion. Passive immunotherapy with monoclonal antibodies is a safe treatment method without severe immune-related adverse reactions. Patient follow-up and evaluation of the efficacy and safety of the drug after the end of the therapy plan continues until today, which allows a more detailed and objective evaluation of the results of immunotherapy according to the purpose of the study.


  • Open Access

    The balance between deception and adaptation: vasculogenic mimicry as a tumor survival strategy

    by E. A. Prosekina, V. A. Shapkina, A. E. Karpov, E. Yu. Fedorutseva, A. S. Artemyeva, Е. Ю. Федоруцева

    Vasculogenic mimicry is a unique process through which tumor cells imitate normal vascular endothelial cells to secure access to the blood flow. In this review, we consider molecular mechanisms underlying this phenomenon and its importance in the context of solid tumor development. We have analyzed survival strategies of tumor cells using vasculogenic mimicry and described potential therapeutic approaches aimed at tumor growth and metastasis suppression. Highlighting the methods of histological and molecular identification of vasculogenic mimicry promotes better understanding of this phenomenon and its early diagnosis. The review focuses on the necessity of further research in the area of vasculogenic mimicry to conceptualize mechanisms underlying carcinogenesis. We have analyzed 109 articles from the leading biomedical databases including SciVerse Scopus, PubMed, Web of Science and RSCI (Russian Science Citation Index) which allowed us to summarize current scientific data and identify the key trends in the area of molecular oncology.


  • Open Access

    A phase III, multicenter, open-label study of dinutuximab beta without/with chemotherapy at the investigator’s choice in patients under 18 years old with bone and soft tissue sarcomas with positive expression GD2 and disease progression during the first-line chemotherapy

    by S. A. Kulyova, S. R. Varfolomeeva, K. I. Kirgizov, E. A. Prosekina, O. M. Romantsova, T. V. Gorbunova

    Introduction. Tumor-associated gangliosides are overexpressed on a large number of tumors. The ratio of the amount of gangliosides varies from one type of tumor to another. Tissue restriction of GD2 expression in normal cells and its presence in a wide range of human tumor diseases has increased the relevance of GD2 as a target for immunooncology drugs.The aim of the study was to improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated and bone sarcomas) by incorporating targeted immunotherapeutic options (passive immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.The primary objective of the study was to analyze the efficacy of tandem use of antiGD2 MA and 2+ line chemotherapy on survival. Secondary targets were overall response rate (complete remission (CR) + partial remission (PR)), tumor control rate (CR + PR + stabilization), duration of response, and immune-associated adverse events.Materials and methods. The clinical study protocol was initiated at the Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia and approved by the local ethics committee No. 8 of 21.05.2021. On the basis of a signed memorandum of cooperation, the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia.The study is prospective. It is planned to evaluate the efficacy and safety of using antiGD2 MA and 2+ line chemotherapy at the investigator's choice in patients under 18 years of age with bone, soft tissue and undifferentiated sarcomas with positive GD2 expression and disease progression/recurrence on/after the 1st line of polychemotherapy.This study screened 40 patients to randomize 10 patients. In the future, an additional set of patients is planned.Conclusion. Based on the results obtained, the efficacy and safety of using a combination of antiGD2 immunotherapy and 2+ line chemotherapy in patients under 18 years of age with refractory and recurrent forms of bone and soft-tissue GD2-positive sarcomas will be concluded.


  • Biological features of tissue and bone sarcomas investigated using an in vitro model of clonal selection

    by N.A. Avdonkina, A.B. Danilova, V.A. Misyurin, E.A. Prosekina, D.V. Girdyuk, N.V. Emelyanova, T.L. Nekhaeva, G.I. Gafton, I.A. Baldueva